0000000000019039

AUTHOR

Ralf Gold

showing 32 related works from this author

Glatiramer acetate during early pregnancy: A prospective cohort study

2016

Background: Only limited data are available on whether glatiramer acetate exposure during pregnancy has an effect on perinatal outcome. Objective: To determine the effect of glatiramer acetate exposure during pregnancy on pregnancy outcomes in women with multiple sclerosis. Methods: We compared the outcome of pregnancies of women with multiple sclerosis exposed to glatiramer acetate with pregnancies unexposed to disease-modifying therapies. Women were enrolled into the German Multiple Sclerosis and Pregnancy registry. A standardized questionnaire was administered during pregnancy and postpartum. Detailed information on course of multiple sclerosis and pregnancy, concomitant medications, lab…

Pregnancymedicine.medical_specialtyObstetricsbusiness.industryMultiple sclerosisBirth weightmedicine.disease03 medical and health sciences0302 clinical medicineNeurologyPremature birthConcomitantmedicine030212 general & internal medicineNeurology (clinical)Glatiramer acetatePregnancy outcomesProspective cohort studybusiness030217 neurology & neurosurgerymedicine.drugMultiple Sclerosis Journal
researchProduct

Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation

2016

Genome-wide study in Germans identifies four novel multiple sclerosis risk genes and confirms already known gene loci.

0301 basic medicineMaleDLEU1MedizinGenome-wide association studyEpigenesis GeneticCohort StudiesResearch ArticlesTranscriptional Regulator ERGGeneticsAged 80 and overGlycine Hydroxymethyltransferaseeducation.field_of_studyMultidisciplinaryDNA methylationSciAdv r-articlesMiddle AgedSHMT13. Good healthddc:DNA-Binding ProteinsERGDNA methylationFemaleMAZFunction and Dysfunction of the Nervous SystemResearch ArticleAdultAdolescentPopulationQuantitative Trait Loci610 Medicine & healthDleu1 ; Dna Methylation ; Erg ; L3mbtl3 ; Maz ; Multiple Sclerosis ; Shmt1 ; Genome-wide Association StudyQuantitative trait locusBiologyMajor histocompatibility complexNeurological DisordersMultiple sclerosis03 medical and health sciencesYoung AdultTranscriptional Regulator ERGHumansGenetic Predisposition to DiseaseL3MBTL3EpigeneticsAlleleeducationAllelesAgedgenome-wide association study030104 developmental biologyGenetic LociCase-Control Studiesbiology.proteinTranscription Factors
researchProduct

Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosi…

2015

Background: Available data suggest that pregnancy exposure to interferon-beta might result in lower mean birth weight and preterm birth. Objective: To determine the effect of interferon-beta exposure during pregnancy on pregnancy outcomes in multiple sclerosis patients. Methods: We compared the pregnancy outcomes of women exposed to interferon-beta with pregnancies unexposed to disease-modifying therapies. Women were enrolled into the German Multiple Sclerosis and Pregnancy Registry. A standardized questionnaire was administered during pregnancy and postpartum. Detailed information on course of multiple sclerosis and pregnancy, concomitant medications, delivery, and outcome of pregnancy was…

AdultPediatricsmedicine.medical_specialtyMultiple SclerosisBirth weightGerman03 medical and health sciences0302 clinical medicinePregnancyGermanymedicineBirth WeightHumansImmunologic Factors030212 general & internal medicineProspective StudiesRegistriesProspective cohort studyPregnancy registryPregnancyInterferon betabusiness.industryMultiple sclerosisInfant NewbornAbnormalities Drug-InducedInterferon-betamedicine.diseaselanguage.human_languageBody HeightAbortion SpontaneousPregnancy ComplicationsFirst trimesterPregnancy Trimester FirstNeurologylanguagePremature BirthFemaleNeurology (clinical)business030217 neurology & neurosurgeryMultiple sclerosis (Houndmills, Basingstoke, England)
researchProduct

PML risk stratification using anti-JCV antibody index and L-selectin

2015

Background: Natalizumab treatment is associated with progressive multifocal leukoencephalopathy (PML) development. Treatment duration, prior immunosuppressant use, and JCV serostatus are currently used for risk stratification, but PML incidence stays high. Anti-JCV antibody index and L-selectin (CD62L) have been proposed as additional risk stratification parameters. Objective: This study aimed at verifying and integrating both parameters into one algorithm for risk stratification. Methods: Multicentric, international cohorts of natalizumab-treated MS patients were assessed for JCV index (1921 control patients and nine pre-PML patients) and CD62L (1410 control patients and 17 pre-PML patient…

0301 basic medicineOncologymedicine.medical_specialtyMultiple SclerosisvirusesMedizinOpportunistic InfectionsAntibodies ViralBioinformaticsRisk AssessmentImmunocompromised Host03 medical and health sciences0302 clinical medicineNatalizumabRisk FactorsInternal medicineHumansMedicineSerologic TestsL-SelectinRisk factorRetrospective Studiesbusiness.industryNatalizumabProgressive multifocal leukoencephalopathyMultiple sclerosisIncidence (epidemiology)Leukoencephalopathy Progressive Multifocalvirus diseasesmedicine.diseaseJC VirusEuropeTreatment Outcome030104 developmental biologyNeurologyRelative riskBiomarker (medicine)Neurology (clinical)businessSerostatusAlgorithmsBiomarkers030217 neurology & neurosurgerymedicine.drugMultiple Sclerosis Journal
researchProduct

Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis

2020

ObjectiveTo determine the prevalence of antibodies to Epstein-Barr virus (EBV) in a large cohort of patients with early multiple sclerosis (MS).MethodsSerum samples were collected from 901 patients with a clinically isolated syndrome (CIS) or early relapsing–remitting multiple sclerosis (RRMS) participating in the German National MS cohort, a prospective cohort of patients with early MS with stringent inclusion criteria. Epstein-Barr nuclear antigen (EBNA)-1 and viral capsid antigen (VCA) antibodies were measured in diluted sera by chemiluminescence immunoassays (CLIAs). Sera of EBNA-1 and VCA antibody-negative patients were retested undiluted by an EBV IgG immunoblot. For comparison, we re…

AdultMaleHerpesvirus 4 HumanMultiple Sclerosis610 Medicine & healthmedicine.disease_causeAntibodies ViralSerology03 medical and health sciences0302 clinical medicineAntigenSeroepidemiologic Studieshemic and lymphatic diseasesGermanymedicineSeroprevalenceHumans1506Registriesddc:610Prospective cohort study610 Medicine & health030304 developmental biologyRetrospective Studies0303 health sciencesClinically isolated syndromebusiness.industryMultiple sclerosisMiddle Agedmedicine.diseaseEpstein–Barr virusddc:Psychiatry and Mental healthImmunologyCohortSurgeryFemaleNeurology (clinical)Function and Dysfunction of the Nervous Systembusiness030217 neurology & neurosurgery
researchProduct

The PTPN22gain-of-function+1858T(+) genotypes correlate with low IL-2 expression in thymomas and predispose to myasthenia gravis

2009

Protein tyrosine phosphatase, non-receptor type 22 (PTPN22) inhibits T-cell activation and interleukin-2 (IL-2) production. The PTPN22(gain-of-function)+1858T(+) genotypes predispose to multiple autoimmune diseases, including early-onset (non-thymomatous) myasthenia gravis (MG). The disease association and the requirement of IL-2/IL-2 receptor signaling for intrathymic, negative T-cell selection have suggested that these genotypes may weaken T-cell receptor (TCR) signaling and impair the deletion of autoreactive T cells. Evidence for this hypothesis is missing. Thymoma-associated MG, which depends on intratumorous generation and export of mature autoreactive CD4(+) T cells, is a model of au…

AdultMalemedicine.medical_specialtyThymomaAdolescentGenotypeThymomaImmunologyBiologymedicine.disease_causePolymorphism Single NucleotideWhite PeopleAutoimmunityPTPN22Young AdultAntigens CDInternal medicineMyasthenia GravisCentral tolerance inductionGeneticsmedicineHumansCTLA-4 AntigenGenetic Predisposition to DiseaseReceptorGenetics (clinical)AgedAged 80 and overT-cell receptorProtein Tyrosine Phosphatase Non-Receptor Type 22Thymus NeoplasmsMiddle Agedmedicine.diseaseMyasthenia gravisEndocrinologyImmunologyInterleukin-2FemaleCentral toleranceGenes & Immunity
researchProduct

A CTLA4high genotype is associated with myasthenia gravis in thymoma patients

2005

Myasthenia gravis (MG) in thymoma patients depends critically on intratumorous generation and export of mature autoreactive CD4+ T cells. Why non-MG thymomas fail to produce CD4+ T cells is unknown. We studied three single-nucleotide polymorphisms of the cytotoxic T-lymphocyte–associated antigen 4(CTLA4) gene in thymoma patients, nonthymoma early-onset MG patients, and control subjects. Surprisingly, the CTLA4high genotype +49A/A, which is protective against several autoimmune diseases, exerted a prominent predisposing effect to paraneoplastic MG in thymoma patients. The unusual disease association with a CTLA4high genotype implies a unique pathogenesis of paraneoplastic MG, with high CTLA4…

AdultMaleThymomaAdolescentGenotypeThymomaDisease Associationchemical and pharmacologic phenomenaPolymorphism Single NucleotidePathogenesis03 medical and health sciences0302 clinical medicineGene FrequencyAntigenAntigens CDhemic and lymphatic diseasesMyasthenia GravisGenotypeHumansMedicineCytotoxic T cellCTLA-4 AntigenChildGeneAgedDemography030304 developmental biology0303 health sciencesbusiness.industryThymus NeoplasmsMiddle Agedmedicine.diseaseAntigens DifferentiationMyasthenia gravis3. Good healthNeurologyImmunologyFemaleNeurology (clinical)business030215 immunologyAnnals of Neurology
researchProduct

Safety of potential breast milk exposure to IFN-β or glatiramer acetate

2019

ObjectiveTo determine whether potential breast milk exposure to interferon-beta (IFN-β) or glatiramer acetate (GA) is safe for the infant.MethodsWe identified 74 infants born to 69 women with MS who breastfed under IFN-β (n = 39), GA (n = 34), or both (n = 1). Women had been enrolled into the German Multiple Sclerosis and Pregnancy Registry during pregnancy. Data were obtained from standardized, telephone-administered questionnaires completed by the mother during pregnancy and at 1, 3, 6, and 12 months postpartum and the infant's take-home medical record.ResultsThe median duration of exposed breastfeeding was 8.5 months (wide interquartile range: 4.9–12.7 months). Physical growth curves dur…

AdultMalePediatricsmedicine.medical_specialtyMultiple Sclerosis41BreastfeedingBreast milkArticleChild DevelopmentPregnancyInterquartile rangemedicineHumansImmunologic FactorsRegistriesGlatiramer acetatePregnancyMilk Humanbusiness.industryPostpartum PeriodInfantGlatiramer AcetateInterferon-betamedicine.disease54Pregnancy ComplicationsBreast FeedingNeurologyFemaleMedian bodyNeurology (clinical)businessBreast feedingPostpartum periodmedicine.drugNeurology - Neuroimmunology Neuroinflammation
researchProduct

Clinical implications of serum neurofilament in newly diagnosed MS patients: a longitudinal multicentre cohort study

2020

Abstract Background We aim to evaluate serum neurofilament light chain (sNfL), indicating neuroaxonal damage, as a biomarker at diagnosis in a large cohort of early multiple sclerosis (MS) patients. Methods In a multicentre prospective longitudinal observational cohort, patients with newly diagnosed relapsing-remitting MS (RRMS) or clinically isolated syndrome (CIS) were recruited between August 2010 and November 2015 in 22 centers. Clinical parameters, MRI, and sNfL levels (measured by single molecule array) were assessed at baseline and up to four-year follow-up. Findings Of 814 patients, 54.7% (445) were diagnosed with RRMS and 45.3% (369) with CIS when applying 2010 McDonald criteria (R…

0301 basic medicineAdultMalemedicine.medical_specialtyResearch paperClinical Decision-MakingIntermediate Filamentslcsh:Medicine610 Medicine & healthNewly diagnosedGeneral Biochemistry Genetics and Molecular BiologyMultiple sclerosis03 medical and health sciences0302 clinical medicineAtrophyMultiple Sclerosis Relapsing-RemittingNeurofilament ProteinsInternal medicineGermanymedicineHumansLongitudinal StudiesProspective Studiesddc:610610 Medicine & healthNeurofilament light chainlcsh:R5-920Clinically isolated syndromebusiness.industryMultiple sclerosislcsh:RMcDonald criteriaGeneral MedicineBiomarkermedicine.diseasesNfL030104 developmental biology030220 oncology & carcinogenesisCohortDisease ProgressionCommentaryBiomarker (medicine)Femalelcsh:Medicine (General)businessPredictionFunction and Dysfunction of the Nervous SystemBiomarkersCohort study
researchProduct

Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets

2021

Infectious diseases are an important consideration in autoimmune conditions such as multiple sclerosis. Infective episodes may trigger relapses and significantly deteriorate the course of the disease. Some immunotherapies may cause increased rates of infection-related adverse events. Thus, infection and vaccine-related issues should be included in the individualized patient-specific treatment strategy and counseling before starting therapy and regularly on treatment. Clinical and epidemiological studies as well as pharmacovigilance data repeatedly demonstrated the safety of the great majority of vaccines in multiple sclerosis patients. Moreover, studies have shown that vaccinations with kil…

0301 basic medicinemedicine.medical_specialtyMedizincladribine tabletsDiseaseReviewimmunizationmultiple sclerosis1117 Public Health and Health Services03 medical and health sciences0302 clinical medicineNatalizumabInternal medicinevaccinePharmacovigilancemedicineddc:610CladribineAdverse effectRC346-42911 Medical and Health SciencesPharmacologybusiness.industryMultiple sclerosisCOVID-19Vaccine efficacymedicine.diseaseVaccinationCoronavirus030104 developmental biologyNeurology1107 ImmunologyNeurology (clinical)Neurology. Diseases of the nervous systembusiness030217 neurology & neurosurgerymedicine.drugTherapeutic Advances in Neurological Disorders
researchProduct

The ageing and myasthenic thymus: a morphometric study validating a standard procedure in the histological workup of thymic specimens.

2008

The thymus is believed to play an important role in the pathogenesis of myasthenia gravis (MG). The 80% of MG patients with anti-acetylcholine receptor autoantibodies fall into three clinical subgroups: 1) thymoma; 2) early-onset MG (<age of 40; EOMG) and 3) late-onset (LOMG; onset after 40). Thymectomy is widely used in EOMG, but its benefits have not been established in randomized controlled trials. A multicenter international trial (MGTX) currently seeks to determine whether thymectomy reduces corticosteroid requirements, and to look for correlations with thymic histology. We here describe the validated, standardized histological workup and reporting system used in this trial.

AdultMaleAgingPathologymedicine.medical_specialtyThymomaAdolescentThymomamedicine.medical_treatmentImmunologyThymus GlandThymus Extractslaw.inventionSex FactorsAtrophyRandomized controlled triallawMyasthenia GravismedicineHumansImmunology and AllergyChildRandomized Controlled Trials as TopicThymus extractThymus Neoplasmbusiness.industryAge FactorsAutoantibodyReproducibility of ResultsThymus NeoplasmsThymectomymedicine.diseaseImmunohistochemistryMyasthenia gravisThymectomyNeurologyFemaleNeurology (clinical)businessJournal of neuroimmunology
researchProduct

Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array

2015

Genome-wide association studies (GWAS) successfully identified various chromosomal regions to be associated with multiple sclerosis (MS). The primary aim of this study was to replicate reported associations from GWAS using an exome array in a large German study. German MS cases (n = 4,476) and German controls (n = 5,714) were genotyped using the Illumina HumanExome v1-Chip. Genotype calling was performed with the Illumina Genome Studio(TM) Genotyping Module, followed by zCall. Single-nucleotide polymorphisms (SNPs) in seven regions outside the human leukocyte antigen (HLA) region showed genome-wide significant associations with MS (P values < 5 × 10(-8) ). These associations have been repor…

Geneticseducation.field_of_studyEpidemiologyPopulationGenome-wide association studySingle-nucleotide polymorphismHuman leukocyte antigenBiologySNPeducationExomeGenotypingGenetics (clinical)Genetic associationGenetic Epidemiology
researchProduct

Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis

2019

Background: The course of multiple sclerosis (MS) shows substantial inter-individual variability. The underlying determinants of disease severity likely involve genetic and environmental factors. Objective: The aim of this study was to assess the impact of APOE and HLA polymorphisms as well as smoking and body mass index (BMI) in the very early MS course. Methods: Untreated patients ( n = 263) with a recent diagnosis of relapsing-remitting (RR) MS or clinically isolated syndrome underwent standardized magnetic resonance imaging (MRI). Genotyping was performed for single-nucleotide polymorphisms (SNPs) rs3135388 tagging the HLA-DRB1*15:01 haplotype and rs7412 (Ɛ2) and rs429358 (Ɛ4) in APOE. …

AdultMaleApolipoprotein EMultiple SclerosisAdolescentPolymorphism Single NucleotideBody Mass IndexYoung Adult03 medical and health sciencesApolipoproteins E0302 clinical medicineAtrophyMedizinische FakultätmedicineHumansSNPGenetic Predisposition to Disease030212 general & internal medicineddc:610Risk factorHLA-DRB1Agedbusiness.industryMultiple sclerosisSmokingNeurodegenerationBrainMiddle Agedmedicine.diseaseNeurologyImmunologyFemaleNeurology (clinical)AtrophybusinessBody mass index030217 neurology & neurosurgeryHLA-DRB1 Chains
researchProduct

Neurofilament is an autoantigenic determinant in myasthenia gravis

1999

Intratumorous expression of a 153-kd protein (p153), which contains an acetylcholine receptor-like epitope, is the only tumor marker described to date that significantly associates with thymoma in paraneoplastic myasthenia gravis (MG). Here, we report that p153 is identical to the midsize neurofilament, as verified by immunohistochemistry, immunofluorescence, and western blot analysis. Furthermore, the acetylcholine receptor-like epitope of the midsize neurofilament (NF-M) was identified by peptide epitope mapping. We also show, using T-cell proliferation assays, a significantly increased response of intratumorous T cells to a recombinant midsize neurofilament fragment in thymoma patients w…

Pathologymedicine.medical_specialtyThymomamusic.instrumentNeurofilamentmedicine.diagnostic_testBiologymedicine.diseaseImmunofluorescenceFollicular hyperplasiaMyasthenia gravisEpitopeNeurologyhemic and lymphatic diseasesmedicineImmunohistochemistryNeurology (clinical)musicAcetylcholine receptorAnnals of Neurology
researchProduct

Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS‐1)

2007

Thymomas are thymic epithelial neoplasms, associated with a variety of autoimmune disorders (especially myasthenia gravis), that apparently result from aberrant intra-tumourous thymopoiesis and export of inefficiently tolerized T-cells to the periphery. The autoimmune regulator (AIRE) drives the expression of self-antigens in the thymic medulla and plays an essential role in ‘central’ tolerance in both humans and mice. However, while inactivating AIRE mutations result in the ‘autoimmune polyendocrinopathy syndrome type 1’ (APS-1), its major features are not well reproduced in AIRE-knock-out mice. Therefore, alternative human disease scenarios with concomitant AIRE deficiency may be valuable…

AdultMaleThymomaAdolescentThymomaAntibodies NeoplasmThymus Glandmedicine.disease_causeAutoantigensAutoimmune DiseasesPathology and Forensic MedicineAutoimmunity03 medical and health sciences0302 clinical medicineAntigens NeoplasmInterferonMyasthenia GravismedicineHumansPolyendocrinopathies AutoimmuneAgedAutoantibodies030304 developmental biologyAged 80 and over0303 health sciencesbiologybusiness.industryAutoantibodyThymus NeoplasmsMiddle AgedAutoimmune regulatormedicine.diseaseImmunohistochemistryMyasthenia gravisNeoplasm Proteins3. Good healthThymic Tissue030220 oncology & carcinogenesisInterferon Type IImmunologybiology.proteinCytokinesFemaleAntibodybusinessTranscription Factorsmedicine.drugThe Journal of Pathology
researchProduct

Treatment choices and neuropsychological symptoms of a large cohort of early MS

2018

ObjectiveTo assess clinical characteristics, distribution of disease-modifying treatments (DMTs), and neuropsychological symptoms in a large cohort of patients with early-stage MS.MethodsThe German National MS Cohort is a multicenter prospective longitudinal cohort study that has recruited DMT-naive patients with clinically isolated syndrome (CIS) and relapsing-remitting MS (RRMS) since 2010. We evaluated their baseline characteristics and the prevalence of neuropsychological symptoms.ResultsOf 1,124 patients, with a 2.2:1 female-to-male ratio and median age at onset of 31.71 years (interquartile range [IQR]: 26.06–40.33), 44.6% and 55.3% had CIS and RRMS, respectively. The median Expanded …

medicine.medical_specialty41610 Medicine & healthArticle03 medical and health sciences0302 clinical medicineQuality of lifeInterquartile rangeInternal medicinemedicineddc:610030212 general & internal medicine10. No inequalityDepression (differential diagnoses)Expanded Disability Status ScaleClinically isolated syndromebusiness.industryMultiple sclerosisNeuropsychologymedicine.disease3. Good healthNeurologyCohortNeurology (clinical)businessFunction and Dysfunction of the Nervous System030217 neurology & neurosurgery
researchProduct

Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective ana…

2014

Abstract Background Mitoxantrone is used on an off-label basis in primary progressive MS (PPMS). ABC -transporter-genotypes are associated with therapeutic response in relapsing/secondary progressive MS (RP/SPMS). Objective To evaluate potential pharmacogenetic response markers for mitoxantrone in PPMS. Methods 41 mitoxantrone-treated PPMS-patients, 155 mitoxantrone-treated RP/SPMS-patients and 43 PPMS-controls were retrospectively assessed for clinical therapy-response and in correlation with four single-nucleotide-polymorphisms in ABCB1 - and ABCG2 -genes. Results 53.7% PPMS-patients were mitoxantrone-responders, in comparison to 78.1% of RP/SPMS-patients (p = 0.039). There was no associa…

AdultMaleOncologymedicine.medical_specialtyTreatment responseATP Binding Cassette Transporter Subfamily Bmedicine.medical_treatmentImmunologyPrimary Progressive Multiple SclerosisPharmacologyInternal medicineGenotypeLack of efficacymedicineRetrospective analysisATP Binding Cassette Transporter Subfamily G Member 2HumansImmunology and AllergyRetrospective StudiesAnalgesicsMitoxantronebusiness.industryImmunosuppressionMiddle AgedMultiple Sclerosis Chronic ProgressiveNeoplasm Proteins3. Good healthNeurologyPharmacogeneticsATP-Binding Cassette TransportersFemaleNeurology (clinical)MitoxantronebusinessPharmacogeneticsmedicine.drugJournal of Neuroimmunology
researchProduct

Low frequency and rare coding variation contributes to multiple sclerosis risk

2018

AbstractMultiple sclerosis is a common, complex neurological disease, where almost 20% of risk heritability can be attributed to common genetic variants, including &gt;230 identified by genome-wide association studies (Patsopoulos et al., 2017). Multiple strands of evidence suggest that the majority of the remaining heritability is also due to the additive effects of individual variants, rather than epistatic interactions between these variants, or mutations exclusive to individual families. Here, we show in 68,379 cases and controls that as much as 5% of this heritability is explained by low-frequency variation in gene coding sequence. We identify four novel genes driving MS risk independe…

Genetics0303 health sciencesLinkage disequilibriumMultiple sclerosisDiseaseBiologyHeritabilitymedicine.disease3. Good health03 medical and health sciences0302 clinical medicinemedicineEpistasisCoding regionGene030217 neurology & neurosurgery030304 developmental biologyGenetic association
researchProduct

cFLIPoverexpression in T cells in thymoma‐associated myasthenia gravis

2015

OBJECTIVE: The capacity of thymomas to generate mature CD4+ effector T cells from immature precursors inside the tumor and export them to the blood is associated with thymoma-associated myasthenia gravis (TAMG). Why TAMG(+) thymomas generate and export more mature CD4+ T cells than MG(-) thymomas is unknown. METHODS: Unfixed thymoma tissue, thymocytes derived thereof, peripheral blood mononuclear cells (PBMCs), T-cell subsets and B cells were analysed using qRT-PCR and western blotting. Survival of PBMCs was measured by MTT assay. FAS-mediated apoptosis in PBMCs was quantified by flow cytometry. NF-κB in PBMCs was inhibited by the NF-κB-Inhibitor, EF24 prior to FAS-Ligand (FASLG) treatment …

0303 health sciencesThymomamedicine.diagnostic_testApoptosis Inhibitorbusiness.industryGeneral Neurosciencemedicine.diseasePeripheral blood mononuclear cellMyasthenia gravisFlow cytometryBlot03 medical and health sciences0302 clinical medicineApoptosishemic and lymphatic diseasesImmunologymedicineCancer researchMTT assayNeurology (clinical)businessResearch Articles030304 developmental biology030215 immunologyAnnals of Clinical and Translational Neurology
researchProduct

A protein quality control pathway regulated by linear ubiquitination.

2019

Neurodegenerative diseases are characterized by the accumulation of misfolded proteins in the brain. Insights into protein quality control mechanisms to prevent neuronal dysfunction and cell death are crucial in developing causal therapies. Here, we report that various disease-associated protein aggregates are modified by the linear ubiquitin chain assembly complex (LUBAC). HOIP, the catalytic component of LUBAC, is recruited to misfolded Huntingtin in a p97/VCP-dependent manner, resulting in the assembly of linear polyubiquitin. As a consequence, the interactive surface of misfolded Huntingtin species is shielded from unwanted interactions, for example with the low complexity sequence doma…

MaleHuntingtinSp1 protein humanProtein aggregationHTT protein humanDeubiquitinating enzymegenetics [Huntington Disease]Micegenetics [Sp1 Transcription Factor]0302 clinical medicineUbiquitinpathology [Brain]Valosin Containing Proteincytology [Fibroblasts]pathology [Neurons]PolyubiquitinCells CulturedMice Knockout0303 health sciencesHuntingtin ProteinGeneral NeuroscienceNF-kappa Bgenetics [Huntingtin Protein]Middle AgedCell biologymetabolism [Polyubiquitin]pathology [Huntington Disease]metabolism [Neurons]metabolism [NF-kappa B]Protein foldingFemalemetabolism [Fibroblasts]Protein BindingSignal TransductionAdultmetabolism [Valosin Containing Protein]Sp1 Transcription Factorcytology [Embryo Mammalian]genetics [Valosin Containing Protein]BiologyGeneral Biochemistry Genetics and Molecular Biologymetabolism [Sp1 Transcription Factor]03 medical and health sciencesddc:570Gene silencingAnimalsHumansmetabolism [Huntington Disease]Protein Interaction Domains and MotifsMolecular Biologymetabolism [Embryo Mammalian]030304 developmental biologyAgedSp1 transcription factorGeneral Immunology and MicrobiologyUbiquitinationProteotoxicitymetabolism [Brain]Case-Control Studiesmetabolism [Huntingtin Protein]biology.proteinProtein Processing Post-Translational030217 neurology & neurosurgerygenetics [NF-kappa B]
researchProduct

MSJ763541_supplementary_material – Supplemental material for Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atroph…

2018

Supplemental material, MSJ763541_supplementary_material for Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis by Christiane Graetz, Adriane Gröge, Felix Luessi, Anke Salmen, Daniela Zöller, Janine Schultz, Nelly Siller, Vinzenz Fleischer, Barbara Bellenberg, Achim Berthele, Viola Biberacher, Joachim Havla, Michael Hecker, Reinhard Hohlfeld, Carmen Infante-Duarte, Jan S Kirschke, Tania Kümpfel, Ralf Linker, Friedemann Paul, Steffen Pfeuffer, Philipp Sämann, Gerrit Toenges, Frank Weber, Uwe K Zettl, Antje Jahn-Eimermacher, Gisela Antony, Sergiu Groppa, Heinz Wiendl, Bernhard Hemmer, Mark Mühlau, Carsten Lukas, Ralf Gold, Chri…

FOS: Clinical medicine111702 Aged Health CareFOS: Health sciences110904 Neurology and Neuromuscular Diseases
researchProduct

A human post-mortem brain model for the standardization of multi-centre MRI studies

2015

Multi-centre MRI studies of the brain are essential for enrolling large and diverse patient cohorts, as required for the investigation of heterogeneous neurological and psychiatric diseases. However, the multi-site comparison of standard MRI data sets that are weighted with respect to tissue parameters such as the relaxation times (T1, T2) and proton density (PD) may be problematic, as signal intensities and image contrasts depend on site-specific details such as the sequences used, imaging parameters, and sensitivity profiles of the radiofrequency (RF) coils. Water or gel phantoms are frequently used for long-term and/or inter-site quality assessment. However, these phantoms hardly mimic t…

Models Anatomicmedicine.medical_specialtyNeurologyCognitive NeuroscienceModels NeurologicalMulti-centre MRI studies; Post-mortem brain; Quantitative MRI; Standardization; Aged; Artifacts; Brain; Female; Humans; Magnetic Resonance Imaging; Multicenter Studies as Topic; Phantoms Imaging; Reproducibility of Results; Models Anatomic; Models Neurological; Postmortem Changes; Cognitive Neuroscience; Neurology; Medicine (all)Cognitive neuroscienceImaging phantomPhantomsImagingWhite matterModelsPost-mortem brainmedicineHumansMulticenter Studies as TopicMagnetization transferMulti-centre MRI studiesAgedmedicine.diagnostic_testbusiness.industryPhantoms ImagingMedicine (all)AnatomicBrainReproducibility of ResultsMagnetic resonance imagingHuman brainQuantitative MRIMagnetic Resonance ImagingStandardizationmedicine.anatomical_structureNeurologyPostmortem ChangesNeurologicalFemaleBrainstemNuclear medicinebusinessArtifacts
researchProduct

Late-onset myasthenia gravis - CTLA4(low) genotype association and low-for-age thymic output of naïve T cells.

2014

Abstract Late-onset myasthenia gravis (LOMG) has become the largest MG subgroup, but the underlying pathogenetic mechanisms remain mysterious. Among the few etiological clues are the almost unique serologic parallels between LOMG and thymoma-associated MG (TAMG), notably autoantibodies against acetylcholine receptors, titin, ryanodine receptor, type I interferons or IL-12. This is why we checked LOMG patients for two further peculiar features of TAMG – its associations with the CTLA4 high/gain-of-function  +49A/A genotype and with increased thymic export of naive T cells into the blood, possibly after defective negative selection in AIRE-deficient thymomas. We analyzed genomic DNA from 116 …

Malemedicine.medical_specialtyGenotypeThymomaT-LymphocytesImmunologyDNA Mutational AnalysisRecent Thymic EmigrantLate onsetCell CountThymus GlandBiologyPeripheral blood mononuclear cellWhite PeopleGene FrequencyInternal medicineGenotypeMyasthenia GravismedicineImmune ToleranceImmunology and AllergyHumansCTLA-4 AntigenGenetic Predisposition to DiseaseGenetic Association StudiesAgedPeripheral tolerance inductionAged 80 and overPolymorphism GeneticThymocytesT-cell receptor excision circlesAutoantibodyCell DifferentiationThymus NeoplasmsMiddle Agedmedicine.diseaseMyasthenia gravisEndocrinologyImmunologyFemaleJournal of autoimmunity
researchProduct

MHCII-independent CD4+ T cells protect injured CNS neurons via IL-4

2015

A body of experimental evidence suggests that T cells mediate neuroprotection following CNS injury; however, the antigen specificity of these T cells and how they mediate neuroprotection are unknown. Here, we have provided evidence that T cell-mediated neuroprotection after CNS injury can occur independently of major histocompatibility class II (MHCII) signaling to T cell receptors (TCRs). Using two murine models of CNS injury, we determined that damage-associated molecular mediators that originate from injured CNS tissue induce a population of neuroprotective, IL-4-producing T cells in an antigen-independent fashion. Compared with wild-type mice, IL-4-deficient animals had decreased functi…

CD4-Positive T-LymphocytesCancer ResearchMAP Kinase Signaling SystemPopulationReceptors Antigen T-CellInflammationBiologyNeuroprotectionMiceAntigenClinical investigationAnimalsMedicineExtracellular Signal-Regulated MAP KinaseseducationReceptorInterleukin 4Mice Knockouteducation.field_of_studybusiness.industryT-cell receptorHistocompatibility Antigens Class IINeurodegenerative DiseasesGeneral MedicineAxonsCell biologyBrain InjuriesMyeloid Differentiation Factor 88Immunologybiology.proteinInterleukin-4medicine.symptomFunction and Dysfunction of the Nervous SystemCorrigendumbusinessProto-Oncogene Proteins c-aktResearch ArticleNeurotrophinJournal of Clinical Investigation
researchProduct

Longitudinal prevalence and determinants of pain in multiple sclerosis: results from the German National Multiple Sclerosis Cohort study

2020

Pain is frequent in multiple sclerosis (MS) and includes different types, with neuropathic pain (NP) being most closely related to MS pathology. However, prevalence estimates vary largely, and causal relationships between pain and biopsychosocial factors in MS are largely unknown. Longitudinal studies might help to clarify the prevalence and determinants of pain in MS. To this end, we analyzed data from 410 patients with newly diagnosed clinically isolated syndrome or relapsing-remitting MS participating in the prospective multicenter German National MS Cohort Study (NationMS) at baseline and after 4 years. Pain was assessed by self-report using the PainDETECT Questionnaire. Neuropsychiatri…

Biopsychosocial modelmedicine.medical_specialtyMultiple SclerosisCohort Studies03 medical and health sciences0302 clinical medicine030202 anesthesiologyInternal medicineEpidemiologyPrevalenceHumansMedicineProspective StudiesProspective cohort study610 Medicine &amp; healthFatigueDepression (differential diagnoses)Clinically isolated syndromeDepressionbusiness.industryMultiple sclerosismedicine.diseaseAnesthesiology and Pain MedicineNeurologyNeuropathic painNeurology (clinical)business030217 neurology & neurosurgeryCohort study
researchProduct

The Autoimmune Regulator AIRE in Thymoma Biology: Autoimmunity and Beyond

2010

Thymomas are tumors of thymic epithelial cells. They associate more often than any other human tumors with various autoimmune diseases; myasthenia gravis is the commonest, occurring in 10-50% of thymoma patients, depending on the World Health Organization-defined histologic subtype. Most thymomas generate many polyclonal maturing T lymphocytes but in disorganized microenvironments Failure to induce self-tolerance may be a key factor leading to the export of potentially autoreactive CD4 progeny, thus predisposing to autoimmune diseases. Normally, the master Autoimmune Regulator promotes expression of peripheral tissue-restricted antigens such as insulin by medullary thymic epithelial cells a…

Pulmonary and Respiratory MedicineThymomaThymomamedicine.medical_treatmentAutoimmunitymedicine.disease_causeWorld healthAutoimmune DiseasesAutoimmunityAntigenAIREhemic and lymphatic diseasesAPS-1HumansMedicineMyasthenia gravisbusiness.industryInsulinThymus NeoplasmsAutoimmune regulatormedicine.diseaseMyasthenia gravisOncologyImmunologybusinessAPECEDTranscription FactorsJournal of Thoracic Oncology
researchProduct

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

2021

Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in recent years have significantly changed the prognosis and course of the disease. This update of the Multiple Sclerosis Therapy Consensus Group treatment recommendation focuses on the most important recommendations for disease-modifying therapies of multiple sclerosis in 2021. Our recommendations are based on current scientific evidence and apply to those medications approved in wide parts of Europe, particular…

Position statementmedicine.medical_specialtytreatment recommendationMedizin610 Medicine & healthReviewDiseasemultiple sclerosis03 medical and health sciences0302 clinical medicineWhite paperNeuronal damagemedicine030212 general & internal medicineRC346-429610 Medicine &amp; healthIntensive care medicinePharmacologybusiness.industryMultiple sclerosisDisease mechanismsGuidelinemedicine.diseasedisease-modifying therapy3. Good healthGroup treatmentNeurologyNeurology. Diseases of the nervous systemNeurology (clinical)businessguideline030217 neurology & neurosurgeryTherapeutic Advances in Neurological Disorders
researchProduct

Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity

2021

AbstractBackgroundMultiple sclerosis (MS) disease risk is associated with reduced sun exposure. This study assessed the relationship between measures of sun-exposure (vitamin D (vitD), latitude) and MS disease severity, the mechanisms of action, and effect-modification by medication and sun-sensitivity associated MC1R variants.MethodsTwo multi-center cohort studies (nNationMS=946, nBIONAT=991). Outcomes were the multiple sclerosis severity score (MSSS) and the number of Gd-enhancing lesion (GELs). RNAseq of four immune cell populations before and after UV-phototherapy of five MS patients.ResultsHigh serum vitD was associated with reduced MSSS (PNationMS=0.021; PBIONAT=0.007) and reduced ris…

medicine.medical_specialty610 Medicine & healthDiseaseGastroenterologyLesionImmune systemInterferonInternal medicineVitamin D and neurologyMedicineddc:610610 Medicine &amp; healthBeneficial effectsSunlightSystemic lupus erythematosusMultidisciplinaryLow latitudebusiness.industryMultiple sclerosismedicine.diseaseddc:Cardiovascular and Metabolic DiseasesDisease riskmedicine.symptombusinessmedicine.drugCohort study
researchProduct

Is APOE ε4 associated with cognitive performance in early MS?

2020

ObjectiveTo assess the impact of APOE polymorphisms on cognitive performance in patients newly diagnosed with clinically isolated syndrome (CIS) or relapsing-remitting MS (RRMS).MethodsThis multicenter cohort study included 552 untreated patients recently diagnosed with CIS or RRMS according to the 2005 revised McDonald criteria. The single nucleotide polymorphisms rs429358 (ε4) and rs7412 (ε2) of the APOE haplotype were assessed by allelic discrimination assays. Cognitive performance was evaluated using the 3-second paced auditory serial addition test and the Multiple Sclerosis Inventory Cognition (MUSIC). Sum scores were calculated to approximate the overall cognitive performance and memo…

OncologyApolipoprotein Emedicine.medical_specialtyClinically isolated syndromemedicine.diagnostic_testPaced Auditory Serial Addition Testbusiness.industryMultiple sclerosisCognitionMcDonald criteria610 Medicine & healthmedicine.diseaseNeurologyInternal medicinemedicineddc:610Neurology (clinical)Effects of sleep deprivation on cognitive performance610 Medicine &amp; healthFunction and Dysfunction of the Nervous SystembusinessCohort study
researchProduct

DeepWAS: Multivariate genotype-phenotype associations by directly integrating regulatory information using deep learning

2020

Genome-wide association studies (GWAS) identify genetic variants associated with traits or diseases. GWAS never directly link variants to regulatory mechanisms. Instead, the functional annotation of variants is typically inferred by post hoc analyses. A specific class of deep learning-based methods allows for the prediction of regulatory effects per variant on several cell type-specific chromatin features. We here describe “DeepWAS”, a new approach that integrates these regulatory effect predictions of single variants into a multivariate GWAS setting. Thereby, single variants associated with a trait or disease are directly coupled to their impact on a chromatin feature in a cell type. Up to…

0301 basic medicineMultivariate analysisGene ExpressionGenome-wide association studyBiochemistry0302 clinical medicineGenotypeMedicine and Health SciencesBiology (General)0303 health sciencesDNA methylationEcologyChromosome BiologyNeurodegenerative DiseasesGenomicsChromatinChromatinNucleic acidsNeurologyComputational Theory and MathematicsModeling and SimulationDNA methylationTraitEpigeneticsDNA modificationFunction and Dysfunction of the Nervous SystemChromatin modificationResearch ArticleMultiple SclerosisQH301-705.5Quantitative Trait LociImmunologySingle-nucleotide polymorphismComputational biologyBiologyQuantitative trait locusPolymorphism Single NucleotideAutoimmune DiseasesMolecular Genetics03 medical and health sciencesCellular and Molecular NeuroscienceDeep LearningGenome-Wide Association StudiesGeneticsHumansGeneMolecular BiologyGenetic Association StudiesEcology Evolution Behavior and Systematics030304 developmental biologyGenetic associationBiology and Life SciencesComputational BiologyHuman GeneticsCell BiologyDNAGenome AnalysisDemyelinating Disorders030104 developmental biologyGenetic LociMultivariate AnalysisClinical ImmunologyClinical Medicine030217 neurology & neurosurgeryGenome-Wide Association StudyPLOS Computational Biology
researchProduct

Identification of inflammatory neuronal injury and prevention of neuronal damage in multiple sclerosis: hope for novel therapies?

2013

Importance Although multiple sclerosis (MS) has long been considered the prototype for an inflammatory, demyelinating disease of the central nervous system, modern histopathology and imaging techniques show that significant damage to neuronal structures already start occurring in the earliest stages of the disease. As the disease progresses, the extent of neuronal pathology accumulates. Therapeutic progress in terms of the prevention of increased disability has only just begun. Objective To review possible diagnostic improvements of neuronal compartment pathology as well as direct therapeutic interventions based on reports from the last decade and outline clinical results from studies and p…

NeuronsMultiple Sclerosisbusiness.industryMultiple sclerosisCentral nervous systemAnti-Inflammatory AgentsDiseasemedicine.diseaseNeuroprotectionClinical trialmedicine.anatomical_structureNeuronal damageNerve DegenerationDemyelinating diseasemedicineDisease ProgressionHumansIdentification (biology)Neurology (clinical)businessNeuroscienceJAMA neurology
researchProduct

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.

2018

Background and purpose: Multiple sclerosis (MS) is a complex disease of the central nervous system. As new drugs are becoming available, knowledge on diagnosis and treatment must continuously evolve. There is therefore a need for a reference tool compiling current data on benefit and safety, to aid professionals in treatment decisions and use of resources across Europe. The European Committee of Treatment and Research in Multiple Sclerosis (ECTRIMS) and the European Academy of Neurology (EAN) have joined forces to meet this need. The objective was to develop an evidence-based clinical practice guideline for the pharmacological treatment of people with MS to guide healthcare professionals in…

medicine.medical_specialtyConsensusMultiple SclerosisdemyelinatingComplex diseasedisease-modifying therapies GRADE methodology guideline Multiple sclerosis Neurology Neurology (clinical)Outcome (game theory)Pharmacological treatmentImmunomodulation03 medical and health sciences0302 clinical medicineIntervention (counseling)GRADE methodologyAgency (sociology)Nominal group techniquemedicineImmunologic FactorsRelevance (law)Humans030212 general & internal medicineneurological disorderdisease-modifying therapiesIntensive care medicineSocieties MedicaldiseaseEvidence-Based Medicinebusiness.industryMultiple sclerosisdisease-modifying treatmentGuidelinemedicine.diseaseresearch methodEuropeNeurologymultiple sclerosiFamily medicinePractice Guidelines as TopicNeurology (clinical)businessguideline030217 neurology & neurosurgeryEuropean journal of neurology
researchProduct